

specification and claims, and reconsider the application in view of the following remarks. In order to facilitate the Examiner's evaluation of the application, the Applicants have attempted to address the Examiner's rejections in the same order in which they were raised in Paper No. 16.

Please amend the application as follows:

Please replace page 10 of the specification with the attached substitute page 10. The particular corrections made in the substitute page are discussed below. None of the changes are deemed to constitute new matter.

SUMMARY OF THE INVENTION

The present invention is directed to a novel class of retroviral vectors that have been engineered to be capable of transducing mammalian cells at such high efficiency that no selection step is required (when used with the appropriate packaging cells lines). Given that no selection is required, the presently described retroviral vectors do not encode a functional selectable marker. This feature of the present vectors renders them novel over all prior art retroviral vectors, and provides the additional advantage that present vectors may incorporate larger inserted genes than previous retroviral vectors.

AMENDMENTS

In the specification:

✓ Replace page 10 with the attached substitute page 10.